Comparison of Apixaban and left atrial appendage exclusion device (Watchman) in preventing stroke and systemic embolism in atrial fibrillation patients

<p>Atrial fibrillation is a cardiac arrhythmia associated with increased risk of stroke and systemic embolism. Apixaban, an oral anticoagulant, and the Watchman, a left atrial appendage closure device, are the currently used therapeutic treatments for the prevention of stroke and systemic embolism in atrial fibrillation patients. However, a direct comparison of these two treatments with respect to safety and effectiveness remains limited. This research evaluates Apixaban and the Watchman device by analysing the clinical trial data and full regulatory approval pathways. Apixaban has been approved through New Drug Application process, and the Watchman device is approved via the premarket approval process. The study highlights the quality and rigorous nature of the New Drug Application and the premarket approval process, indicating the safety and efficacy of Apixaban and the Watchman device. This research emphasizes the need for individualised treatment decisions for atrial fibrillation patients.</p>

Name thesis:degree_name

Master of Science (MS)

Level thesis:degree_level

Open Access Thesis

Discipline thesis:degree_discipline

Health Sciences

Year dc:date.available

2025

Author dc:creator

• Konatham, Sreeja

Contributors dc:contributor

• Michael Switzer, Ph.D.
• Shannon Murray, MHS

• Apixaban
• Left Atrial Appendage
• NDA
• PMA
• Watchman
• Watchman Device
• Medicine and Health Sciences
• Surgery

Repository record dc:identifier

https://commons.emich.edu/theses/1300

OAI identifier oai:identifier

oai:commons.emich.edu:theses-2632